Enhanced potential of Myricx' NMT inhibitor payloads

UK biotech start-up Myricx Bio has announced the publication today of ground-breaking research in Nature Cell Biology by its collaborators at the MRC-LMS (Laboratory of Medical Sciences) that has uncovered the central role of NMT as a druggable pathway in senescence.

The company is focused on the discovery and development of a completely novel class of antibody-drug conjugate (ADC) payloads based on N-Myristoyltransferase (NMT) inhibition,

The research, funded by UKRI MRC and CRUK, involved a major collaborative study led by Myricx’s scientific consultant and collaborator, Professor Jesús Gil, lead author of the study and head of the Senescence Research Group at MRC-LMS, together with Myricx co-founder Professor Ed Tate, and 18 other scientists, discovered that small molecule NMTis can selectively kill senescent cancer cells.